A new Proposal for a Quasielectron Trial Wavefunction for the FQHE on a Disk

In this letter, we propose a new quasielectron trial wavefunction for $N$ interacting electrons in two dimensions moving in a strong magnetic field in a disk geometry. Requiring that the trial wavefunction exhibits the correct filling factor of a quasielectron wavefunction, we obtain $N+1$ angular momentum eigenfunctions. The expectation values of the energy are calculated and compared with the data of an exact numerical diagonalization.Comment: 8 page

Extrinsic Curvature Embedding Diagrams

Embedding diagrams have been used extensively to visualize the properties of curved space in Relativity. We introduce a new kind of embedding diagram based on the {\it extrinsic} curvature (instead of the intrinsic curvature). Such an extrinsic curvature embedding diagram, when used together with the usual kind of intrinsic curvature embedding diagram, carries the information of how a surface is {\it embedded} in the higher dimensional curved space. Simple examples are given to illustrate the idea.Comment: 22 pages, 4 figure

Expanding Cosmologies in Brane Geometries

Five dimensional gravity coupled, both in the bulk and on a brane, to a scalar Liouville field yields a geometry confined to a strip around the brane and with time dependent scale factors for the four geometry. In various limits known models can be recovered as well as a temporally expanding four geometry with a warp factor falling exponentially away from the brane. The effective theory on the brane has a time dependent Planck mass and ``cosmological constant''. Although the scale factor expands, the expansion is not an acceleration.Comment: 7 pages, LaTex/RevTex

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials

<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with acute ischemic stroke treated with intravenous tissue plasminogen activator within 3 hours of symptom onset who were enrolled in the placebo arms of 2 trials (Stroke-Acute Ischemic NXY Treatment [SAINT] I and II Trials) of a putative neuroprotectant. Early CT changes were graded using the Alberta Stroke Program Early CT Score (ASPECTS). Post–tissue plasminogen activator symptomatic intracerebral hemorrhage was defined as a worsening in National Institutes of Health Stroke Scale of ≥4 points within 36 hours with evidence of hemorrhage on follow-up neuroimaging. Good clinical outcome was defined as a modified Rankin scale of 0 to 2 at 90 days.</p> <p><b>Results:</b> Symptomatic intracerebral hemorrhage occurred in 5.6% of 965 patients treated with tissue plasminogen activator. In multivariable analysis, symptomatic intracerebral hemorrhage was increased with baseline antiplatelet use (single antiplatelet: OR, 2.04, 95% CI, 1.07 to 3.87, P=0.03; double antiplatelet: OR, 9.29, 3.28 to 26.32, P<0.001), higher National Institutes of Health Stroke Scale score (OR, 1.09 per point, 1.03 to 1.15, P=0.002), and CT changes defined by ASPECTS (ASPECTS 8 to 9: OR, 2.26, 0.63 to 8.10, P=0.21; ASPECTS ≤7: OR, 5.63, 1.66 to 19.10, P=0.006). Higher National Institutes of Health Stroke Scale was associated with decreased odds of good clinical outcome (OR, 0.82 per point, 0.79 to 0.85, P<0.001). There was no relationship between baseline antiplatelet use or CT changes and clinical outcome.</p> <p><b>Conclusions:</b> Along with higher National Institutes of Health Stroke Scale and extensive early CT changes, baseline antiplatelet use (particularly double antiplatelet therapy) was associated with an increased risk of post–tissue plasminogen activator symptomatic intracerebral hemorrhage. Of these factors, only National Institutes of Health Stroke Scale was associated with clinical outcome.</p&gt

Berry phases for composite fermions: effective magnetic field and fractional statistics

The quantum Hall superfluid is presently the only viable candidate for a realization of quasiparticles with fractional Berry phase statistics. For a simple vortex excitation, relevant for a subset of fractional Hall states considered by Laughlin, non-trivial Berry phase statistics were demonstrated many years ago by Arovas, Schrieffer, and Wilczek. The quasiparticles are in general more complicated, described accurately in terms of excited composite fermions. We use the method developed by Kjonsberg, Myrheim and Leinaas to compute the Berry phase for a single composite-fermion quasiparticle, and find that it agrees with the effective magnetic field concept for composite fermions. We then evaluate the "fractional statistics", related to the change in the Berry phase for a closed loop caused by the insertion of another composite-fermion quasiparticle in the interior. Our results support the general validity of fractional statistics in the quantum Hall superfluid, while also giving a quantitative account of corrections to it when the quasiparticle wave functions overlap. Many caveats, both practical and conceptual, are mentioned that will be relevant to an experimental measurement of the fractional statistics. A short report on some parts of this article has appeared previously.Comment: 14 pages, 9 figure

A maximum density rule for surfaces of quasicrystals

A rule due to Bravais of wide validity for crystals is that their surfaces correspond to the densest planes of atoms in the bulk of the material. Comparing a theoretical model of i-AlPdMn with experimental results, we find that this correspondence breaks down and that surfaces parallel to the densest planes in the bulk are not the most stable, i.e. they are not so-called bulk terminations. The correspondence can be restored by recognizing that there is a contribution to the surface not just from one geometrical plane but from a layer of stacked atoms, possibly containing more than one plane. We find that not only does the stability of high-symmetry surfaces match the density of the corresponding layer-like bulk terminations but the exact spacings between surface terraces and their degree of pittedness may be determined by a simple analysis of the density of layers predicted by the bulk geometric model.Comment: 8 pages of ps-file, 3 Figs (jpg

Thermodynamics of Quantum Hall Ferromagnets

The two-dimensional interacting electron gas at Landau level filling factor $\nu =1$ and temperature $T=0$ is a strong ferromagnet; all spins are completely aligned by arbitrarily weak Zeeman coupling. We report on a theoretical study of its thermodynamic properties using a many-body perturbation theory approach and concentrating on the recently measured temperature dependence of the spin magnetization. We discuss the interplay of collective and single-particle aspects of the physics and the opportunities for progress in our understanding of itinerant electron ferromagnetism presented by quantum Hall ferromagnets.Comment: REVTex, 10 pages, 3 uuencoded, compressed and tarred PostScript figures appende

Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention

MRI; Milvexian; Stroke preventionResonancia magnética; Milvexian; Prevención de ictusRessonància magnètica; Milvexian; Prevenció d'ictusBackground Individuals with ischemic stroke or transient ischemic attack (TIA) have a high early risk of ischemic stroke despite dual antiplatelet therapy. The risk of ischemic stroke, and associated disability, represents a significant unmet clinical need. Genetic variants resulting in reduced factor XI levels are associated with reduced risk for ischemic stroke but are not associated with increased intracranial bleeding. Milvexian is an oral small-molecule inhibitor of FXIa that binds activated factor XI with high affinity and selectivity and may reduce the risk of stroke when added to antiplatelet drugs without significant bleeding. We aimed to evaluate the dose-response relationship of milvexian in participants treated with dual antiplatelets. Methods We began a phase II, double-blinded, randomized, placebo-controlled trial at 367 sites in 2019. Participants (N = 2366) with ischemic stroke (National Institutes of Health Stroke Scale score ≤7) or high-risk TIA (ABCD2 score ≥6) were randomized to 1 of 5 doses of milvexian or placebo for 90 days. Participants also received clopidogrel 75 mg daily for the first 21 days and aspirin 100 mg for 90 days. The efficacy endpoint was the composite of ischemic stroke or incident infarct on magnetic resonance imaging. Major bleeding, defined as type 3 or 5 bleeding according to the Bleeding Academic Research Consortium, was the safety endpoint. Participant follow-up will end in 2022. Conclusion The AXIOMATIC-SSP trial will evaluate the dose-response of milvexian for ischemic stroke occurrence in participants with ischemic stroke or TIA.This study is sponsored by Bristol Myers Squibb and Janssen Research & Development, LLC

A Snapshot of J. L. Synge

A brief description is given of the life and influence on relativity theory of Professor J. L. Synge accompanied by some technical examples to illustrate his style of work

Brane World Cosmology In Jordan-Brans-Dicke Theory

We consider the embedding of 3+1 dimensional cosmology in 4+1 dimensional Jordan-Brans-Dicke theory. We show that exponentially growing and power law scale factors are implied. Whereas the 4+1 dimensional scalar field is approximately constant for each, the effective 3+1 dimensional scalar field is constant for exponentially growing scale factor and time dependent for power law scale factor.Comment: 11 page